1. Reiter A et al. Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma. Hematology 2007; 1: 285–96.
2. Burkhardt В, Oschlies I, Klapper W et al. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 2011; 25: 153–60.
3. Ковригина А.М., Пробатова Н.А. Лимфома Ходжкина и крупноклеточные лимфомы. М.: МИА, 2007; с. 212. / Kovrigina A.M., Probatova N.A. Limfoma Khodzhkina i krupnokletochnye limfomy. M.: MIA, 2007; s. 212. [in Russian]
4. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2008.
5. Reiter A et al. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Hematol 2008; 142: 329–47.
6. Jaffe ES et al. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology 2011; 506–14.
7. Heerema NA, Bernheim AB, Lim MS et al. Meeting report, State of the art and future needs in cytogenetic/molecular genetics/arrays in childhood lymphoma: summary report of workshop at the first international symposium on childhood and adolescent non-Hodgkin lymphoma. Ped Blood Cancer 2005; 45: 616–22.
8. Oschlies I et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Francfurt-Munster) multicenter trial. Blood 2006; 107 (10): 4047–52.
9. Miles R, Raphael M, McCarthy et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) International Study Group. Ped Blood Cancer 2008; 51 (3): 369–74.
10. Валиев Т.Т., Морозова О.В., Ковригина А.М. и др. Диагностика и лечение анапластических крупноклеточных лимфом у детей. Гематология и трансфузиология. 2012; 51 (1): 3–9. / Valiev T.T., Morozova O.V., Kovrigina A.M. i dr. Diagnostika i lechenie anaplasticheskikh krupnokletochnykh limfom u detei. Gematologiia i transfuziologiia. 2012; 51 (1): 3–9. [in Russian]
11. Барышников А.Ю., Валиев Т.Т., Губин А.Н. Лимфомы у детей: практ. рук. Под ред. Г.Л.Менткевича, С.А.Маяковой. М.: Практическая медицина, 2014. / Baryshnikov A.Iu., Valiev T.T., Gubin A.N. Limfomy u detei: prakt. ruk. Pod red. G.L.Mentkevicha, S.A.Maiakovoi. M.: Prakticheskaia meditsina, 2014. [in Russian]
12. Pillon M et al. Long-term results of the first Italian association of pediatric hematology and oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer 2004; 101 (2): 385–94.
13. Reiter A, Schrappe M, Tieman M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster group Trial NHL-BFM90. Blood 1999; 94 (10): 3294–306.
14. Laver JH, Kraveka JM, Hutchison RE et al. Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III Trial. J Clin Oncol 2005; 23 (3): 541–7.
15. Woessmann W, Seidemann K, Mann G et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood 2005; 105 (3): 948–58.
16. Cairo M, Sposto R, Gerrard M. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescents age (>15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol 2012; 30 (4): 387–93.
17. Patte C, Auperin A, Gerard M et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773–80.
18. Gerrard M, Waxman IM, Sposto R et al. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood 2013; 121 (2): 278–85.
19. Worth J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents – review of standartd chemotherapy regimen and perspectives. Ped Hematol Oncol 2013; 30: 465–83.
20. Tsurusawa M, Mori T, Kikuchi A et al. Improved treatment results of Children with B-cell non-Hodgkin lymphoma: a report from Japanese pediatric leukemia/lymphoma study group B-NHL03 study. Ped Blood Cancer 2014; 61: 1215–21.
21. Goldman S, Smith L, Anderson JR et al. Rituximab and FAB/LMB96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology group report. Leukemia 2013; 27: 1174–7.
22. Barth MJ, Goldman S, Smith L et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukemia: a Children’s Oncology group report. Br J Haematol 2013; 162: 678–83.
23. Самочатова Е.В., Шелихова Л.Н., Мякова Н.В. Лечение диффузной Б-крупноклеточной лимфомы у детей с применением интенсивной химиотерапии с ритуксимабом: предварительные результаты. Детская онкология. 2007; 3–4: 51–6. / Samochatova E.V., Shelikhova L.N., Miakova N.V. Lechenie diffuznoi B-krupnokletochnoi limfomy u detei s primeneniem intensivnoi khimioterapii s rituksimabom: predvaritel'nye rezul'taty. Detskaia onkologiia. 2007; 3–4: 51–6. [in Russian]
24. Самочатова Е.В., Шелихова Л.Н., Белогурова М.Б. Комбинированная химиоиммунотерапия больных неходжкинскими лимфомами из зрелых В-клеток возрастной группы до 18 лет: результаты многоцентрового исследования НХЛ2004м с применением ритуксимаба и модифицированного протокола Б-НХЛ БФМ 90. Онкогематология. 2009; 3: 4–14. / Samochatova E.V., Shelikhova L.N., Belogurova M.B. Kombinirovannaia khimioimmunoterapiia bol'nykh nekhodzhkinskimi limfomami iz zrelykh V-kletok vozrastnoi gruppy do 18 let: rezul'taty mnogotsentrovogo issledovaniia NKhL2004m s primeneniem rituksimaba i modifitsirovannogo protokola B-NKhL BFM 90. Onkogematologiia. 2009; 3: 4–14. [in Russian]
25. Самочатова Е.В., Шелихова Л.Н., Мякова Н.В. Возможности и проблемы современной терапии неходжкинских лимфом у детей и подростков. Педиатрия. 2011; 90 (4): 37–43. / Samochatova E.V., Shelikhova L.N., Miakova N.V. Vozmozhnosti i problemy sovremennoi terapii nekhodzhkinskikh limfom u detei i podrostkov. Pediatriia. 2011; 90 (4): 37–43. [in Russian]
26. Lange J et al. Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience. Curr Hematol Malig Rep 2013; 8 (3): 226–35.
27. Meinhardt A, Burkhardt B, Zimmermann M et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt Leukemia. J Clin Oncol 2010; 28 (19): 3115–21.
28. Meyer PN, Fu K, Greiner TG et al. Immunohistocemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29 (2): 200–7.
29. Hu S, Xu-Monette ZY, Tzankov A et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP consortium program. Blood 2013; 121 (20): 4021–31.
30. Wilson WH, Jung SH et al. A cancer and leukemia group B multi-center study of DA-EPOCH – rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Hematologyca 2012; 97 (5): 758–65.
31. Нечунаева И.Н., Агеева Т.А., Маслова Л.М. Эффективность лечения диффузных В-клеточных крупноклеточных лимфом по данным городского гематологического центра г. Новосибирска. Бюллетень СО РАМН. 2011; 31 (2): 71–4. / Nechunaeva I.N., Ageeva T.A., Maslova L.M. Effektivnost' lecheniia diffuznykh V-kletochnykh krupnokletochnykh limfom po dannym gorodskogo gematologicheskogo tsentra g. Novosibirska. Biulleten' SO RAMN. 2011; 31 (2): 71–4. [in Russian]
32. Klapper W, Kreuz M, Kohler CW et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 2012; 119 (8): 1882–7.
33. Chen Y, Sun XF, Cai RQ. Germinal-center type B-cell classification and clinical characteristics of Chinese pediatric diffuse large B-cell lymphoma: a report of 76 cases. Chin J Cancer 2013; 32 (10): 561–6.
34. Poirel HA, Cairo MS, Heerema NA et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia 2009; 23 (2): 323–31.
35. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immuhistochemistry using a tissue microarray. Blood 2004; 103 (1): 275–82.
36. Hoeller S, Schneider A, Haralambieva E et al. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, indepemdent of gains and structural aberrations at 3p14.1. Histopathology 2010; 57: 73–80.
37. Perry AM, Zdravko M et al. Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control 2012; 19 (3): 214–26.
38. Culpin RE, Sieniawski M, Angus B et al. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. Histopathology 2013; 63: 788–801.
39. Visco Y, Li Y, Xu-Monette ZY et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Prorram Study. Leukemia 2012.
40. Troppan K, Wenzl K, Deutsch A et al. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 2014; 34: 557–64.
41. Guo Y, Takeuchi I, Karnan S et al. Array-comparative genomic hybridization profiling of immunohistochemical subgroups of diffuse large B-cell lymphoma shows distinct genomic alterations. Cancer Sci 2014; 105 (4): 481–9.
42. Scott DW, Wright GW, Williams PM et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123 (8): 1214–7.
43. Deffenbacher KE, Iqbal J, Sanger W et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood 2012; 119 (16): 3757–66.
44. Мисюрина А.Е., Мисюрин В.А., Барях Е.А., Ковригина А.М. Роль экспрессии генов C-MYC, BCL2, BCL6 в патогенезе диффузной В-крупноклеточной лимфомы. Клин. онкогематология. 2014; 7 (4): 512–21. / Misiurina A.E., Misiurin V.A., Bariakh E.A., Kovrigina A.M. Rol' ekspressii genov C-MYC, BCL2, BCL6 v patogeneze diffuznoi V-krupnokletochnoi limfomy. Klin. onkogematologiia. 2014; 7 (4): 512–21. [in Russian]
45. Johnson NA, Slack GW, Savage KJ et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphomide, doxorubicin, vincristine and prednisone. J Clinical Oncol 2012; 30 (28): 3452–8.
46. Perry AM, Alvarado-Bernal Y, Laurini JA et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol 2014; 165: 382–91.
47. Valera A, Lopez-Guillermo A, Cardesa-Salzmann T et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013; 98 (10): 1554–62.
48. Horn H, Ziepert M, Becher C et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B cell lymphoma. Blood 2013; 121: 2253–63.
49. Tzankov A, Xu-Monette Z, Gerhard M et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathol 2014; 27: 958–71.
50. Visco C, Tzankov A, Xu-Monette Z et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP consortium program study. Haematologica 2013; 98 (2): 255–63.
51. Hu S, Xu-Monette ZY, Balasubramanyam A et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013; 121: 2715–24.
52. Ok CJ, Xu-Monette ZY, Tzankov A et al. STAT3 expression and clinical inplications in de novo diffuse large B cell lymphoma: a report from the International DLBCL Rituximab-CHOP consortium program. Blood 2013; 122: 21.
53. Wu ZL, Song YQ, Shi YF et al. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol 2011; 4 (31): 1–6.
54. Ok CY, Chen J, Xu-Monette Z et al. Clinical implications of phosphorylated STAT3 expre ssion in de novo diffuse large B-cell lymphoma. Clin Cancer Res 2014.
55. Soldini D, Montagna C, Schuffer P et al. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome. Ann Oncol 2013; 24: 193–201.
56. Aquino G, Marra L, De Chiara A et al. MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas. Infect Agents Cancer 2013; 8: 37.
57. Dunleavy K, Pittaluga S, Shovlin M et al. Concurrent expression of MYC/BCL2 protein in newly diagnosed DLBCL is not associated with an inferior survival following EPOCH-R therapy. Blood 2013; 122: 21.
58. Мисюрина А.Е., Ковригина А.М., Барях А.Е. Экспрессия белков MYC и BCL2 у больных с диффузной В-крупноклеточной лимфомой. Клин. онкогематология. 2015; 8 (1): 44–53. / Misiurina A.E., Kovrigina A.M., Bariakh A.E. Ekspressiia belkov MYC i BCL2 u bol'nykh s diffuznoi V-krupnokletochnoi limfomoi. Klin. onkogematologiia. 2015; 8 (1): 44–53. [in Russian]
59. Ichikava S, Fukuhara N, Katsushima H et al. Association between BACH2 expression and clinical prognosis in diffuse large B cell lymphoma. Cancer Sci 2014; 105 (4): 437–44.
60. Yamamoto W et al. Human leukocyte antigen – DR expression on flow cytometry and tumor associated macrophages in diffuse large B cell lymphoma treated by: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cogort study. Leukemia/Lymphoma 2014; 55 (12): 2721–7.
61. Miyazaki K. Yamaguchi M, Suzuki R et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011; 22: 1601–7.
62. Laurent C, Do C, Gascoyne RD et al. Anaplastic lymphoma kinase – positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol 2009; 27 (25): 4211–6.
63. Valera A, Colomo L, Martinez A et al. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Modern Pathol 2013; 26: 1329–37.
64. Cox CM, Di Napoli A., Scarpino S et al. Clinicopathologic characterization of diffuse large B cell lymphoma with an associated serum monoclonal IgM component.
65. Roschewski M, Dunleavy K, Wilson WH. Diffuse large B-cell lymphoma: molecular targeted therapy. Int J Hematol 2012; 96 (5): 552–61.
66. Horie R. Molecularly-targeted strategy and NFkB in lymphoid malignancies. J Clin Experiment Hematopathol 2013; 53 (3): 185–95.
67. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma – treatment approaches in the molecular era. Nature. Reviews. Clin Oncol 2014; 11 (1): 12–23.
68. Nagel D, Vincendeau M, Eitelhuber AC et al. Mechanisms and consequences of constitutive NFkB activation in B-cell lymphoid malignancies. Oncogene 2014; p. 1–11.
69. Schneider C, Pasqualucci L, Dalla-Favera R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagnost Pathol 2011; 28: 167–77.
70. Witzig TE et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011; 25: 341–7.
71. Furman RR, Martin P, Ruan J et al. Phase1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 2010; p. 5432–9.
72. Ruan J, Martin P, Furman RR et al. Bortezomib plus CHOP-Rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clinical Oncol 2011; 29 (6): 690–7.
73. Maishman T, Stanton L, Davies A et al. A novel adaptive trial design: randomized evaluation of molecular guided therapy for diffuse large B-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy. Trials 2013; 14: 77.
74. Johnston PB et al. Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B-cell lymphoma (DLBCL): A phase I and feasibility study (NCCTG N1085). J Clin Oncol 2015; 33 (Suppl.; abstr 8518).
75. Nam SJ et al. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leukemia Lymphoma 2014; 55 (11): 2466–76.
76. Xie M et al. The prognostic significance of tumor-associated macrophages and NK cells in patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2014; 124 (21).
77. Togunaga T, Tomita A, Sugimoto K et al. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. Cancer Sci 2014; 105 (1): 35–43.
78. Song G, Cho WC, Gu L et al. Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Med Oncol 2014.
79. Fen Liu et al. FCGR3A 158 V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA Cell Biol 2014; 33: 616–23.
80. Morschhauser FA et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the Phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912–9.
81. Coiffier B et al. A multicentre, phase II trial ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Hematol 2013; 163: 334–42.
82. Bartlett N et al. Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL). J Clinl Oncol 2015; 33 (Suppl.; abstr 8506).
83. Younes A, Bartlett NL, Leonard JP et al. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med 2010; 363: 1812–21.
84. Pro B et al. Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30 (18): 2190–6.
85. http://www.childrensoncologygroup.org. A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117.
86. Wagner-Johnston ND et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B cell lymphoma. Leukemia Lymphoma 2015; p. 1–7.
87. Гаврилина О.А., Габеева Н.Г., Морозова А.К. Роль высокодозной химиотерапии и аутотрансплантации стволовых клеток крови у пациентов с диффузной В крупноклеточной лимфомой. Терапевт. арх. 2013; 7: 90–7. / Gavrilina O.A., Gabeeva N.G., Morozova A.K. Rol' vysokodoznoi khimioterapii i autotransplantatsii stvolovykh kletok krovi u patsientov s diffuznoi V krupnokletochnoi limfomoi. Terapevt. arkh. 2013; 7: 90–7. [in Russian]
88. Rytting M et al. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Ped Blood Cancer 2014; 61 (2): 369–72.
89. Friedberg J et al. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Hematol 2014; 166 (3): 382–9.
90. Briones J et al. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica 2014; 99 (3): 505–10.
91. Cooney-Qualter E et al. A phase I study of yttrium-90 ibritumomab tiuxitan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin lymphoma: a Children’s Oncology Group Study. Clin Cancer Res 2007; 13: 5652–60.
92. Kraeber-Bodere F et al. Consolidation anti-CD22 fractionated radioimmunotherapy (RIT) with 90Y- epratuzumab tetraxetan following R-CHOP in elderly diffuse large B cell lymphoma (DLBCL) patients. J Nucl Med 2013; 54 (Suppl. 2): 179.
93. Witzig TE et al. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica 2014; 99 (11): 1738–45.
94. Viardot A et al. Treatment of relapsed/refractory diffuse large B cell lymphoma with the bispecific T-cell engager (BiTE) antibody construct blinatumomab: primary analysis results from an open-label, phase II study. ASH annual meeting abstracts book, 2014; p. 4460.
95. Portell CA et al. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol Adv Appl 2013; 5: 5–11.
96. Schlegel P et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014; 99 (7): 1212–18.
97. Stackelberg A et al. Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. ASH annual meeting abstracts book, 2014; p. 2292.
98. Schuster FR et al. Immunotherapy with trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in pediatric high-risk patients with recurrent CD20-positive B-cell malignancies. Br J Haematol 2015; 169 (1): 90–102.
99. Kochenderfer JN et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T-cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014; p. 1–11.
100. Wang Y et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol 2014; 155: 160–75.
101. Maude S et al. Chimeric antigen receptor (CAR) modified N cells induce durable remissions in children with relapsed/refractory ALL. ASPHO annual meeting book, 2015; p. 4003.
102. Suzuki M et al. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Ped Blood Cancer 2015; 62: 1326–36.

________________________________________________

1. Reiter A et al. Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma. Hematology 2007; 1: 285–96.
2. Burkhardt В, Oschlies I, Klapper W et al. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 2011; 25: 153–60.
3. Kovrigina A.M., Probatova N.A. Limfoma Khodzhkina i krupnokletochnye limfomy. M.: MIA, 2007; s. 212. [in Russian]
4. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2008.
5. Reiter A et al. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Hematol 2008; 142: 329–47.
6. Jaffe ES et al. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology 2011; 506–14.
7. Heerema NA, Bernheim AB, Lim MS et al. Meeting report, State of the art and future needs in cytogenetic/molecular genetics/arrays in childhood lymphoma: summary report of workshop at the first international symposium on childhood and adolescent non-Hodgkin lymphoma. Ped Blood Cancer 2005; 45: 616–22.
8. Oschlies I et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Francfurt-Munster) multicenter trial. Blood 2006; 107 (10): 4047–52.
9. Miles R, Raphael M, McCarthy et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) International Study Group. Ped Blood Cancer 2008; 51 (3): 369–74.
10. Valiev T.T., Morozova O.V., Kovrigina A.M. i dr. Diagnostika i lechenie anaplasticheskikh krupnokletochnykh limfom u detei. Gematologiia i transfuziologiia. 2012; 51 (1): 3–9. [in Russian]
11. Baryshnikov A.Iu., Valiev T.T., Gubin A.N. Limfomy u detei: prakt. ruk. Pod red. G.L.Mentkevicha, S.A.Maiakovoi. M.: Prakticheskaia meditsina, 2014. [in Russian]
12. Pillon M et al. Long-term results of the first Italian association of pediatric hematology and oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer 2004; 101 (2): 385–94.
13. Reiter A, Schrappe M, Tieman M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster group Trial NHL-BFM90. Blood 1999; 94 (10): 3294–306.
14. Laver JH, Kraveka JM, Hutchison RE et al. Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III Trial. J Clin Oncol 2005; 23 (3): 541–7.
15. Woessmann W, Seidemann K, Mann G et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood 2005; 105 (3): 948–58.
16. Cairo M, Sposto R, Gerrard M. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescents age (>15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol 2012; 30 (4): 387–93.
17. Patte C, Auperin A, Gerard M et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773–80.
18. Gerrard M, Waxman IM, Sposto R et al. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood 2013; 121 (2): 278–85.
19. Worth J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents – review of standartd chemotherapy regimen and perspectives. Ped Hematol Oncol 2013; 30: 465–83.
20. Tsurusawa M, Mori T, Kikuchi A et al. Improved treatment results of Children with B-cell non-Hodgkin lymphoma: a report from Japanese pediatric leukemia/lymphoma study group B-NHL03 study. Ped Blood Cancer 2014; 61: 1215–21.
21. Goldman S, Smith L, Anderson JR et al. Rituximab and FAB/LMB96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology group report. Leukemia 2013; 27: 1174–7.
22. Barth MJ, Goldman S, Smith L et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukemia: a Children’s Oncology group report. Br J Haematol 2013; 162: 678–83.
23. Samochatova E.V., Shelikhova L.N., Miakova N.V. Lechenie diffuznoi B-krupnokletochnoi limfomy u detei s primeneniem intensivnoi khimioterapii s rituksimabom: predvaritel'nye rezul'taty. Detskaia onkologiia. 2007; 3–4: 51–6. [in Russian]
24. Samochatova E.V., Shelikhova L.N., Belogurova M.B. Kombinirovannaia khimioimmunoterapiia bol'nykh nekhodzhkinskimi limfomami iz zrelykh V-kletok vozrastnoi gruppy do 18 let: rezul'taty mnogotsentrovogo issledovaniia NKhL2004m s primeneniem rituksimaba i modifitsirovannogo protokola B-NKhL BFM 90. Onkogematologiia. 2009; 3: 4–14. [in Russian]
25. Samochatova E.V., Shelikhova L.N., Miakova N.V. Vozmozhnosti i problemy sovremennoi terapii nekhodzhkinskikh limfom u detei i podrostkov. Pediatriia. 2011; 90 (4): 37–43. [in Russian]
26. Lange J et al. Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience. Curr Hematol Malig Rep 2013; 8 (3): 226–35.
27. Meinhardt A, Burkhardt B, Zimmermann M et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt Leukemia. J Clin Oncol 2010; 28 (19): 3115–21.
28. Meyer PN, Fu K, Greiner TG et al. Immunohistocemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29 (2): 200–7.
29. Hu S, Xu-Monette ZY, Tzankov A et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP consortium program. Blood 2013; 121 (20): 4021–31.
30. Wilson WH, Jung SH et al. A cancer and leukemia group B multi-center study of DA-EPOCH – rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Hematologyca 2012; 97 (5): 758–65.
31. Nechunaeva I.N., Ageeva T.A., Maslova L.M. Effektivnost' lecheniia diffuznykh V-kletochnykh krupnokletochnykh limfom po dannym gorodskogo gematologicheskogo tsentra g. Novosibirska. Biulleten' SO RAMN. 2011; 31 (2): 71–4. [in Russian]
32. Klapper W, Kreuz M, Kohler CW et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 2012; 119 (8): 1882–7.
33. Chen Y, Sun XF, Cai RQ. Germinal-center type B-cell classification and clinical characteristics of Chinese pediatric diffuse large B-cell lymphoma: a report of 76 cases. Chin J Cancer 2013; 32 (10): 561–6.
34. Poirel HA, Cairo MS, Heerema NA et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia 2009; 23 (2): 323–31.
35. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immuhistochemistry using a tissue microarray. Blood 2004; 103 (1): 275–82.
36. Hoeller S, Schneider A, Haralambieva E et al. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, indepemdent of gains and structural aberrations at 3p14.1. Histopathology 2010; 57: 73–80.
37. Perry AM, Zdravko M et al. Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control 2012; 19 (3): 214–26.
38. Culpin RE, Sieniawski M, Angus B et al. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. Histopathology 2013; 63: 788–801.
39. Visco Y, Li Y, Xu-Monette ZY et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Prorram Study. Leukemia 2012.
40. Troppan K, Wenzl K, Deutsch A et al. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 2014; 34: 557–64.
41. Guo Y, Takeuchi I, Karnan S et al. Array-comparative genomic hybridization profiling of immunohistochemical subgroups of diffuse large B-cell lymphoma shows distinct genomic alterations. Cancer Sci 2014; 105 (4): 481–9.
42. Scott DW, Wright GW, Williams PM et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123 (8): 1214–7.
43. Deffenbacher KE, Iqbal J, Sanger W et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood 2012; 119 (16): 3757–66.
44. Misiurina A.E., Misiurin V.A., Bariakh E.A., Kovrigina A.M. Rol' ekspressii genov C-MYC, BCL2, BCL6 v patogeneze diffuznoi V-krupnokletochnoi limfomy. Klin. onkogematologiia. 2014; 7 (4): 512–21. [in Russian]
45. Johnson NA, Slack GW, Savage KJ et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphomide, doxorubicin, vincristine and prednisone. J Clinical Oncol 2012; 30 (28): 3452–8.
46. Perry AM, Alvarado-Bernal Y, Laurini JA et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol 2014; 165: 382–91.
47. Valera A, Lopez-Guillermo A, Cardesa-Salzmann T et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013; 98 (10): 1554–62.
48. Horn H, Ziepert M, Becher C et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B cell lymphoma. Blood 2013; 121: 2253–63.
49. Tzankov A, Xu-Monette Z, Gerhard M et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathol 2014; 27: 958–71.
50. Visco C, Tzankov A, Xu-Monette Z et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP consortium program study. Haematologica 2013; 98 (2): 255–63.
51. Hu S, Xu-Monette ZY, Balasubramanyam A et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013; 121: 2715–24.
52. Ok CJ, Xu-Monette ZY, Tzankov A et al. STAT3 expression and clinical inplications in de novo diffuse large B cell lymphoma: a report from the International DLBCL Rituximab-CHOP consortium program. Blood 2013; 122: 21.
53. Wu ZL, Song YQ, Shi YF et al. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol 2011; 4 (31): 1–6.
54. Ok CY, Chen J, Xu-Monette Z et al. Clinical implications of phosphorylated STAT3 expre ssion in de novo diffuse large B-cell lymphoma. Clin Cancer Res 2014.
55. Soldini D, Montagna C, Schuffer P et al. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome. Ann Oncol 2013; 24: 193–201.
56. Aquino G, Marra L, De Chiara A et al. MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas. Infect Agents Cancer 2013; 8: 37.
57. Dunleavy K, Pittaluga S, Shovlin M et al. Concurrent expression of MYC/BCL2 protein in newly diagnosed DLBCL is not associated with an inferior survival following EPOCH-R therapy. Blood 2013; 122: 21.
58. Misiurina A.E., Kovrigina A.M., Bariakh A.E. Ekspressiia belkov MYC i BCL2 u bol'nykh s diffuznoi V-krupnokletochnoi limfomoi. Klin. onkogematologiia. 2015; 8 (1): 44–53. [in Russian]
59. Ichikava S, Fukuhara N, Katsushima H et al. Association between BACH2 expression and clinical prognosis in diffuse large B cell lymphoma. Cancer Sci 2014; 105 (4): 437–44.
60. Yamamoto W et al. Human leukocyte antigen – DR expression on flow cytometry and tumor associated macrophages in diffuse large B cell lymphoma treated by: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cogort study. Leukemia/Lymphoma 2014; 55 (12): 2721–7.
61. Miyazaki K. Yamaguchi M, Suzuki R et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011; 22: 1601–7.
62. Laurent C, Do C, Gascoyne RD et al. Anaplastic lymphoma kinase – positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol 2009; 27 (25): 4211–6.
63. Valera A, Colomo L, Martinez A et al. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Modern Pathol 2013; 26: 1329–37.
64. Cox CM, Di Napoli A., Scarpino S et al. Clinicopathologic characterization of diffuse large B cell lymphoma with an associated serum monoclonal IgM component.
65. Roschewski M, Dunleavy K, Wilson WH. Diffuse large B-cell lymphoma: molecular targeted therapy. Int J Hematol 2012; 96 (5): 552–61.
66. Horie R. Molecularly-targeted strategy and NFkB in lymphoid malignancies. J Clin Experiment Hematopathol 2013; 53 (3): 185–95.
67. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma – treatment approaches in the molecular era. Nature. Reviews. Clin Oncol 2014; 11 (1): 12–23.
68. Nagel D, Vincendeau M, Eitelhuber AC et al. Mechanisms and consequences of constitutive NFkB activation in B-cell lymphoid malignancies. Oncogene 2014; p. 1–11.
69. Schneider C, Pasqualucci L, Dalla-Favera R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagnost Pathol 2011; 28: 167–77.
70. Witzig TE et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011; 25: 341–7.
71. Furman RR, Martin P, Ruan J et al. Phase1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 2010; p. 5432–9.
72. Ruan J, Martin P, Furman RR et al. Bortezomib plus CHOP-Rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clinical Oncol 2011; 29 (6): 690–7.
73. Maishman T, Stanton L, Davies A et al. A novel adaptive trial design: randomized evaluation of molecular guided therapy for diffuse large B-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy. Trials 2013; 14: 77.
74. Johnston PB et al. Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B-cell lymphoma (DLBCL): A phase I and feasibility study (NCCTG N1085). J Clin Oncol 2015; 33 (Suppl.; abstr 8518).
75. Nam SJ et al. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leukemia Lymphoma 2014; 55 (11): 2466–76.
76. Xie M et al. The prognostic significance of tumor-associated macrophages and NK cells in patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2014; 124 (21).
77. Togunaga T, Tomita A, Sugimoto K et al. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. Cancer Sci 2014; 105 (1): 35–43.
78. Song G, Cho WC, Gu L et al. Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Med Oncol 2014.
79. Fen Liu et al. FCGR3A 158 V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA Cell Biol 2014; 33: 616–23.
80. Morschhauser FA et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the Phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912–9.
81. Coiffier B et al. A multicentre, phase II trial ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Hematol 2013; 163: 334–42.
82. Bartlett N et al. Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL). J Clinl Oncol 2015; 33 (Suppl.; abstr 8506).
83. Younes A, Bartlett NL, Leonard JP et al. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med 2010; 363: 1812–21.
84. Pro B et al. Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30 (18): 2190–6.
85. http://www.childrensoncologygroup.org. A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117.
86. Wagner-Johnston ND et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B cell lymphoma. Leukemia Lymphoma 2015; p. 1–7.
87. Gavrilina O.A., Gabeeva N.G., Morozova A.K. Rol' vysokodoznoi khimioterapii i autotransplantatsii stvolovykh kletok krovi u patsientov s diffuznoi V krupnokletochnoi limfomoi. Terapevt. arkh. 2013; 7: 90–7. [in Russian]
88. Rytting M et al. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Ped Blood Cancer 2014; 61 (2): 369–72.
89. Friedberg J et al. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Hematol 2014; 166 (3): 382–9.
90. Briones J et al. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica 2014; 99 (3): 505–10.
91. Cooney-Qualter E et al. A phase I study of yttrium-90 ibritumomab tiuxitan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin lymphoma: a Children’s Oncology Group Study. Clin Cancer Res 2007; 13: 5652–60.
92. Kraeber-Bodere F et al. Consolidation anti-CD22 fractionated radioimmunotherapy (RIT) with 90Y- epratuzumab tetraxetan following R-CHOP in elderly diffuse large B cell lymphoma (DLBCL) patients. J Nucl Med 2013; 54 (Suppl. 2): 179.
93. Witzig TE et al. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica 2014; 99 (11): 1738–45.
94. Viardot A et al. Treatment of relapsed/refractory diffuse large B cell lymphoma with the bispecific T-cell engager (BiTE) antibody construct blinatumomab: primary analysis results from an open-label, phase II study. ASH annual meeting abstracts book, 2014; p. 4460.
95. Portell CA et al. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol Adv Appl 2013; 5: 5–11.
96. Schlegel P et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014; 99 (7): 1212–18.
97. Stackelberg A et al. Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. ASH annual meeting abstracts book, 2014; p. 2292.
98. Schuster FR et al. Immunotherapy with trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in pediatric high-risk patients with recurrent CD20-positive B-cell malignancies. Br J Haematol 2015; 169 (1): 90–102.
99. Kochenderfer JN et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T-cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014; p. 1–11.
100. Wang Y et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol 2014; 155: 160–75.
101. Maude S et al. Chimeric antigen receptor (CAR) modified N cells induce durable remissions in children with relapsed/refractory ALL. ASPHO annual meeting book, 2015; p. 4003.
102. Suzuki M et al. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Ped Blood Cancer 2015; 62: 1326–36.

А.С.Левашов*1, Т.Т.Валиев1, А.М.Ковригина2, А.В.Попа1, Г.Л.Менткевич1

1 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
2 ФГБУ Гематологический научный центр Минздрава России. 125167, Россия, Москва, Новый Зыковский пр., д. 4
*andreyslevashov@mail.ru

________________________________________________

A.S.Levashov*1, T.T.Valiev1, A.M.Kovrigina2, A.V.Popa1, G.L.Mentkevich1

1 N.N.Blokhin Russian Cancer Research Center. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23;
2 National Research Center for Hematology of the Ministry of Health of the Russian Federation. 125167, Russian Federation, Moscow, Novyi Zykovskii pr., d. 4
*andreyslevashov@mail.ru